A new drug application (NDA) has been submitted to the FDA seeking approval of rusfertide, an investigational hepcidin mimetic, for the treatment of adult patients with polycythemia vera (PV). 1 ...

Polycythemia vera is a rare condition that affects the bone marrow, which is slow to progress and typically develops in later life. It is a condition characterized by the overproduction of red blood ...

Polycythemia vera is a classic myeloproliferative neoplasm and a chronic type of leukemia, which often leads to overproduction of various blood cells. In this interview, Andrew Kuykendall, MD, ...

Secondary polycythemia is the overproduction of red blood cells. It causes your blood to thicken, which increases the risk of a stroke. It’s a rare condition. The primary function of your red blood ...

Takeda and Protagonist Therapeutics have submitted a new drug application to the FDA for rusfertide for adults with polycythemia vera.

With treatment, many people with Polycythemia vera (PV) will live at least 14 years after diagnosis. The younger you are, the better your outlook, though other factors can also affect life expectancy.

LIVER tumors, usually hepatomas, are relatively frequent in cases of hepatic cirrhosis, occurring in approximately 3 or 4 per cent of patients with alcoholic cirrhosis and in a somewhat higher ...

Persistent itching can sometimes signal serious illness, including cancer. Oncologist Dr Amit Garg highlights four ...

Dublin, Feb. 17, 2025 (GLOBE NEWSWIRE) -- The "Polycythemia Vera - Market Insight, Epidemiology, and Market Forecast - 2034" report has been added to ResearchAndMarkets.com's offering. The report ...

The polycythemia vera market over the next few years is expected to substantially change and experience growth, as it will be dominated by two already approved products, Incyte/Novartis' JAKAFI and ...